Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-04-17
2007-04-17
Gupta, Anish (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000, C530S383000
Reexamination Certificate
active
10172712
ABSTRACT:
The present invention relates to methods of introducing one or more cysteine residues into a polypeptide which permit the stabilization of the polypeptide by formation of at least one bond, preferably a disulfide bond, between different domains of the polypeptide. The invention also relates to polypeptides containing such introduced cysteine residue(s), nucleic acids encoding such polypeptides and pharmaceutical compositions comprising such polypeptides or nucleic acids. The invention also relates to vectors, viral particles and host cells containing such nucleic acids, and methods of using them to produce the polypeptides of the invention. Exemplified polypeptides include plasma proteins, including hepatocyte growth factor activator and plasma hyaluronin binding protein, as well as blood coagulation factors, such as Factor VIII, Factor V, Factor XII and prothrombin.
REFERENCES:
patent: 4749780 (1988-06-01), Andersson et al.
patent: 4757006 (1988-07-01), Toole, Jr. et al.
patent: 4868112 (1989-09-01), Toole, Jr.
patent: 4877614 (1989-10-01), Andersson et al.
patent: 5009889 (1991-04-01), Taylor, Jr. et al.
patent: 5082767 (1992-01-01), Hatfield et al.
patent: 5198349 (1993-03-01), Kaufman
patent: 5214033 (1993-05-01), Zimmerman et al.
patent: 5422260 (1995-06-01), Kaufman et al.
patent: 5453937 (1995-09-01), Srinivasan et al.
patent: 5543149 (1996-08-01), Rubin
patent: 5661008 (1997-08-01), Almstedt et al.
patent: 5747654 (1998-05-01), Pastan et al.
patent: 5849688 (1998-12-01), Townes et al.
patent: 5869292 (1999-02-01), Voorberg
patent: 6114148 (2000-09-01), Seed et al.
patent: 6180371 (2001-01-01), Lollar
patent: 6358703 (2002-03-01), Cho et al.
patent: WO 93/20212 (1993-10-01), None
patent: WO 96/21035 (1996-07-01), None
patent: WO 96/36366 (1996-11-01), None
patent: WO 98/34640 (1998-08-01), None
patent: WO 03/087355 (2003-10-01), None
Pantoliano et al. “Protein Engineering of Substilsin BPN': Enhanced Stabilization Through the Introduction of Two Cysteines to Form a Disulfide Bond.” Biochemistry, vol. 26, pp. 2077-2082. 1987.
Arai et al. Characterization of Thrombin Cleavage Site Mutation (ARG 1689 to CYS) in the Factor VIII Gene of Two Unrelated Patients with Cross-Reacting Material-Positive Hemophilia A. Blood vol. 75, No. 2, pp. 384-389. Jan. 15, 1990.
Boedeker, B. G. D., “Production Processes of Licensed Recombinant Factor VIII Preparations,”Seminars in Thrombosis and Hemostasis, 27(4):385-394, Aug. 2001.
Bray, G. L. et al., “A Multicenter Study of Recombinant Factor VII (Recombinate): Safety, Efficacy, and Inhibitor Risk in Previously Untreated Patients With Hemophilia A,”Blood, 83(9):2428-2435, May 1, 1994.
Brinkhous, K. M. et al., “Purified human factor VIII procoagulant protein: Comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs,”Proc. Natl. Acad. Sci. USA, 82:8752-8756, Dec. 1985.
Chao, H. et al., “Sustained expression of human factor VIII in mice using a parvovirus-based vector,”Blood, 95(5):1594-1599, Mar. 2000.
Chao, H. et al., “Induction of tolerance to human factor VIII in mice,” (http://www.ncbi.nlm.nih.gov:80/entrez/q...PubMed&list—uids=11342466&dopt=Abstract),Blood, 97(10):3311-3312, May 15, 2001.
Choi-Miura, N-H et al. “Purification and Characterization of a Novel Hyaluronan-Binding Protein (BHBP) from Human Plasma: It Has Three EGF, a Kringle and a Serine Domain, Similar to Hepatocyte Factor Activator,”J. Biochem, 119:1157-1165, 1996.
Cochrane, C. G. et al. The Biochemistry and Pathophysiology of the Contact System of Plasma,Advances In Immunology, 33:241-306, 1982.
Colman, R. W. et al., “Biologic Activities of the ContactIn Vivo,” Thromb. Haemost, 82:1568-1577, 1999.
Cool, D. E. et al., “Characterization of Human Blood Coagulation Factor XII cDNA,”J. Bio. Chem., 260(25):13666-13676, Nov. 5, 1985.
Cote, H. C. F. et al., “Functional Characterization of Recombinant Human Meizothrombin and Meizothrombin (desFl),”J. Biol. Chem., 272(10):6194-6200, Mar. 1997.
DeLa Cadena, R.A, Wachtfogel, YT and Colman RW. Contact Activation Pathway: Inflammation and Coagulation. In Hemostasis and Thrombosis: Basic Principles and Clinical Practice, Third Edition. Eds. R W Colman, J Hirsh, VJ Marder and EW Salzman. JB Lippincott Company, Philadelphia, 1994.
Doyle, M. F. et al., “Meizothrombin: Active Intermediate Formed during Prothrombinase-Catalyzed Acivation of Prothrombin,”Methods Enzymol, 222:299-312, 1990.
Edge, M. D. et al., “Total synthesis of a human leukocyte interferon gene,”Nature, 292:756-762, Aug. 20, 1981.
Fass, D. N. et al., “Monoclonal Antibodies to Porcine Factor VIII Coagulant and Their Use in the Isolation of Active Coagulant Protein,”Blood, 59(3):594-600, Mar. 1982.
Fay, P. J. et al., “Model for the Factor VIIIa-dependent Decay of the Intrinsic Factor Xase,”J.Biol. Chem., 271(11):6027-6032, Mar. 1996.
Friezner Degen, S. J. et al, “Characterization of the complementary Deoxyribonucleic Acid and Gene Coding for Human Prothrombin,”Biochemistry, 22(9):2087-2097, Apr. 26, 1983.
Fulcher, C. A. et al., “Characterization of the human factor VIII procoagulant protein with a heterologous precipitating antibody,”Proc. Natl. Acad. Sci. USA, 79:1648-1652, Mar. 1982.
Gale et al., “Mechanism Of Factor Va Inactivation By Activated Protein C Clarified Using Engineered Disulfide Bond Between A2 and A3 Domains In Va,” Abstract No. OC869, Supplement toThromb&Haemos, 84:849-857, 2000.
Giangrande, P. L. F., “Safety and efficacy of KOGENATE® Bayer in previously untreated patients (PUPs) and minimally treated patients (MTPs),”Haemophilia, 8(Suppl. 2):19-22, 2002.
Gitschier, J. et al., “Characterization of the human factor VIII gene,”Nature, 312:326-330, Nov. 22, 1984.
Griffin, J.H. et al, “Recent Advances In The Understanding Of Contact Activation Reactions,”Seminars in Thrombosis and Homeostasis, 5(4):254-273, 1979.
Hackeng, T. M. et al., “Protein C activation on endothelial cells by prothrombin activation products generatedin situ: meizothrombin is a better protein C activator than -thrombin,”Biochem. J., 319:399-405, 1996.
High, K. A., “Gene Transfer as an Approach to Treating Hemophilia,”Circ Research, 88:137-144, 2001.
Huggett, B. et al., “EntreMed, Cell Genesys Report Promising Cancer Gene Therapy: GenStar Therapeutics Corp.,” (excerpt),BioWorld Today, p. 4, Jun. 2001.
Jay, E. et al., “Chemical Synthesis of a Biologically Active Gene for Human Immune Interferon-,”J. Biol. Chem., 259(10):6311-6317, May 25, 1984.
Jenny, R. J. et al., “Complete cDNA and derived amino acid sequence of human factor V,”Proc. Natl. Acad. Sci. USA, 84(14):4846-4850, Jul. 1987.
Kafri, T. et al., “Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors,”Nature Genetics, 17:314-317, Nov. 1997.
Lacroix-Desmazes, S. et al., “The Prevalence of Proteolytic Antibodies Against Factor VIII in Hemophilia A,”N. Engl. J. Med., 346(9):662-667, Feb. 28, 2002.
Lind, P. et al., “Novel forms of B-domain-deleted recombinant factor VIII molecules: Construction and biochemical characterization,”Eur. J. Biochem., 232(1):19-27, Aug. 1995.
Lusher, J. M. et al., “Antibody and Inhibitor Patterns in Previously Untreated Patients (PUPs) Treated Exclusively With B-Domain Deleted Recombinant Factor VIII (BDDrFVIII),”Blood, 96:266a, Abstract #1144, 2000.
Lusher, J. M. et al., “Recombinant Factor VIII For The Treatment Of Previously Untreated Patients With Hemophilia A,”New Engl. J. Med., 328(7):453-459, Feb. 18, 1993.
Mann, K. G. et al., “Prothrombin and Thrombin,”Hemostasis and Thrombosis: Basic Principles and Clinical Practice, Third Edition, Chapter 9,184-199, 1994.
Mannucci, P. M. et al.,
Gale Andrew J.
Getzoff Elizabeth D.
Griffin John H.
Pellequer Jean-Luc
Gupta Anish
Morgan & Finnegan L.L.P.
The Scripps Research Institute
LandOfFree
Stabilized proteins with engineered disulfide bonds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stabilized proteins with engineered disulfide bonds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stabilized proteins with engineered disulfide bonds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3752035